T세포 림프종의 동향과 예측
세계의 T세포 림프종 시장은 2024-2030년의 CAGR이 6.5%로, 2030년까지 추정 33억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 세계에서 T세포 림프종의 이환율 상승, 암치료에 관한 기술의 진보, CAR-T세포 치료 및 면역관문억제제를 포함한 면역치료의 사용 증가입니다. 세계의 T세포 림프종 시장의 미래는 방사선요법, 화학요법, 면역치료, 줄기세포 이식의 각 시장에서의 기회에 의해 유망시되고 있습니다.
T세포 림프종 시장 인사이트
Lucintel의 예측에서 말초성 T세포 림프종이 예측 기간 중 가장 높은 성장을 달성할 전망입니다. 이것은 소아 및 젋은 성인에게서 대부분 보이며, 성장이 느린유형의 림프종이나 치료가 어려운 경우가 있습니다.
북미는 T세포 림프종의 이환율이 높은 것, 주요 업계 참여 기업이 존재하는 것, 연구개발 활동이 활발한 것으로 인해 예측 기간 중에도 최대 지역을 유지할 것으로 생각됩니다.
아래 11개의 주요 질문에 대해 답변합니다. :
- Q.1.시장 부문 중 가장 유망하고 고성장인 기회는 무엇인가?
- Q.2.향후 성장이 가속하는 부문과 이유는?
- Q.3.향후 성장이 가속할 것으로 생각되는 지역과 이유는?
- Q.4.시장 역학에 영향을 미치는 주요 요인은 무엇인가? 시장에서 주요 과제와 비즈니스 리스크는?
- Q.5.이 시장에서 비즈니스 리스크와 경쟁의 위협은?
- Q.6.이 시장에서 새로운 동향과 이유는?
- Q.7.시장에서 고객의 수요 변화에는 어떤 것이 있는가?
- Q.8.이 시장에서 새로운 개발과 개발을 선도하고 있는 기업은?
- Q.9.이 시장의 주요 기업은? 주요 기업은 사업 성장을 위해 어떤 전략적 구상을 진행시키고 있는가?
- Q.10.이 시장에서 경쟁 제품은 무엇이며, 재료 및 제품의 대체에 의한 시장 점유율 하락의 위협은 어느 정도인가?
- Q.11.과거 5년간 어떤 M&A가 시행되고, 업계에 어떤 영향을 미쳤는가?
목차
제1장 주요 요약
제2장 세계의 T세포 림프종 시장 : 시장 역학
- 서론, 배경, 분류
- 공급망
- 업계의 촉진요인과 과제
제3장 2018-2030년의 시장 동향과 예측 분석
- 거시경제 동향(2018-2023년)과 예측(2024-2030년)
- 세계의 T세포 림프종 시장 동향(2018-2023년)과 예측(2024-2030년)
- 유형별 세계의 T세포 림프종 시장
- 말초성 T세포 림프종
- 피부 T세포 림프종
- 미분화 대세포 림프종
- 혈관 면역 아구성 T세포 림프종
- 요법별 세계의 T세포 림프종 시장
- 방사선요법
- 화학요법
- 면역치료
- 줄기세포 이식
- 기타
제4장 2018-2030년의 지역별 시장 동향과 예측 분석
- 지역별 세계의 T세포 림프종 시장
- 북미의 T세포 림프종 시장
- 유럽의 T세포 림프종 시장
- 아시아태평양의 T세포 림프종 시장
- 기타 지역의 T세포 림프종 시장
제5장 경쟁 분석
- 제품 포트폴리오 분석
- 운영상의 통합
- Porter's Five Forces 분석
제6장 성장 기회와 전략적 분석
- 성장 기회 분석
- 유형별 세계의 T세포 림프종 시장의 성장 기회
- 요법별 세계의 T세포 림프종 시장의 성장 기회
- 지역별 세계의 T세포 림프종 시장의 성장 기회
- 세계의 T세포 림프종 시장의 새로운 동향
- 전략적 분석
- 신제품의 개발
- 세계의 T세포 림프종 시장의 능력 확대
- 세계의 T세포 림프종 시장에서의 합병, 인수, 합병사업
- 인증과 라이선싱
제7장 유력 기업의 기업 개요
- Johnson & Johnson
- Novartis
- Bristol Myers Squibb Company
- Merck
- F. Hoffmann-La Roche
KSA
T-Cell Lymphoma Trends and Forecast
The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets. The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030 with a CAGR of 6.5% from 2024 to 2030. The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.
A more than 150-page report is developed to help in your business decisions.
T-Cell Lymphoma by Segment
The study includes a forecast for the global T-cell lymphoma by type, therapy, and region.
T-Cell Lymphoma Market by Type [Shipment Analysis by Value from 2018 to 2030]:
- Peripheral T-Cell Lymphoma
- Cutaneous T-Cell Lymphoma
- Anaplastic Large Cell Lymphoma
- Angio-Immuno-Blastic T-Cell Lymphoma
T-Cell Lymphoma Market by Therapy [Shipment Analysis by Value from 2018 to 2030]:
- Radiotherapy
- Chemotherapy
- Immunotherapy
- Stem Cell Transplantation
- Others
T-Cell Lymphoma Market by Region [Shipment Analysis by Value from 2018 to 2030]:
- North America
- Europe
- Asia Pacific
- The Rest of the World
List of T-Cell Lymphoma Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies T-cell lymphoma companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the T-cell lymphoma companies profiled in this report include-
- Johnson & Johnson
- Novartis
- Bristol Myers Squibb Company
- Merck
- F. Hoffmann-La Roche
T-Cell Lymphoma Market Insights
Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.
North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.
Features of the Global T-Cell Lymphoma Market
Market Size Estimates: T-cell lymphoma market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: T-cell lymphoma market size by type, therapy, and region in terms of value ($B).
Regional Analysis: T-cell lymphoma market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different type, therapy, and regions for the T-cell lymphoma market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the T-cell lymphoma market.
Analysis of competitive intensity of the industry based on Porter's Five Forces model.
FAQ
Q1. What is the T-cell lymphoma market size?
Answer: The global T-cell lymphoma market is expected to reach an estimated $3.3 billion by 2030.
Q2. What is the growth forecast for T-cell lymphoma market?
Answer: The global T-cell lymphoma market is expected to grow with a CAGR of 6.5% from 2024 to 2030.
Q3. What are the major drivers influencing the growth of the T-cell lymphoma market?
Answer: The major drivers for this market are rising incidence of T-cell lymphomas globally, advances in technologies related to cancer treatment, and growing usage of immunotherapies, including car-t cell therapies and immune checkpoint inhibitors.
Q4. What are the major segments for T-cell lymphoma market?
Answer: The future of the global T-cell lymphoma market looks promising with opportunities in the radiotherapy, chemotherapy, immunotherapy, and stem cell transplantation markets.
Q5. Who are the key T-cell lymphoma market companies?
Answer: Some of the key T-cell lymphoma companies are as follows:
- Johnson & Johnson
- Novartis
- Bristol Myers Squibb Company
- Merck
- F. Hoffmann-La Roche
Q6. Which T-cell lymphoma market segment will be the largest in future?
Answer: Lucintel forecasts that peripheral T-cell lymphoma is expected to witness the highest growth over the forecast period because it is increasingly found in children and young adults, which is slow-growing type of lymphoma, but it can be difficult to treat.
Q7. In T-cell lymphoma market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to high T-cell lymphoma prevalence, existence of major industry participants, and rise in R&D activities.
Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
- Q.1. What are some of the most promising, high-growth opportunities for the T-cell lymphoma market by type (peripheral T-cell lymphoma, cutaneous T-cell lymphoma, anaplastic large cell lymphoma, and angio-immuno-blastic T-cell lymphoma), therapy (radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
- Q.2. Which segments will grow at a faster pace and why?
- Q.3. Which region will grow at a faster pace and why?
- Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
- Q.5. What are the business risks and competitive threats in this market?
- Q.6. What are the emerging trends in this market and the reasons behind them?
- Q.7. What are some of the changing demands of customers in the market?
- Q.8. What are the new developments in the market? Which companies are leading these developments?
- Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
- Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
- Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
Table of Contents
1. Executive Summary
2. Global T-Cell Lymphoma Market : Market Dynamics
- 2.1: Introduction, Background, and Classifications
- 2.2: Supply Chain
- 2.3: Industry Drivers and Challenges
3. Market Trends and Forecast Analysis from 2018 to 2030
- 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
- 3.2. Global T-Cell Lymphoma Market Trends (2018-2023) and Forecast (2024-2030)
- 3.3: Global T-Cell Lymphoma Market by Type
- 3.3.1: Peripheral T-cell Lymphoma
- 3.3.2: Cutaneous T-cell Lymphoma
- 3.3.3: Anaplastic Large Cell Lymphoma
- 3.3.4: Angio-Immuno-blastic T-cell Lymphoma
- 3.4: Global T-Cell Lymphoma Market by Therapy
- 3.4.1: Radiotherapy
- 3.4.2: Chemotherapy
- 3.4.3: Immunotherapy
- 3.4.4: Stem Cell Transplantation
- 3.4.5: Others
4. Market Trends and Forecast Analysis by Region from 2018 to 2030
- 4.1: Global T-Cell Lymphoma Market by Region
- 4.2: North American T-Cell Lymphoma Market
- 4.2.2: North American T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
- 4.3: European T-Cell Lymphoma Market
- 4.3.1: European T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
- 4.3.2: European T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
- 4.4: APAC T-Cell Lymphoma Market
- 4.4.1: APAC T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
- 4.4.2: APAC T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
- 4.5: ROW T-Cell Lymphoma Market
- 4.5.1: ROW T-Cell Lymphoma Market by Type: Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, and Angio-Immuno-blastic T-cell Lymphoma
- 4.5.2: ROW T-Cell Lymphoma Market by Therapy: Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, and Others
5. Competitor Analysis
- 5.1: Product Portfolio Analysis
- 5.2: Operational Integration
- 5.3: Porter's Five Forces Analysis
6. Growth Opportunities and Strategic Analysis
- 6.1: Growth Opportunity Analysis
- 6.1.1: Growth Opportunities for the Global T-Cell Lymphoma Market by Type
- 6.1.2: Growth Opportunities for the Global T-Cell Lymphoma Market by Therapy
- 6.1.3: Growth Opportunities for the Global T-Cell Lymphoma Market by Region
- 6.2: Emerging Trends in the Global T-Cell Lymphoma Market
- 6.3: Strategic Analysis
- 6.3.1: New Product Development
- 6.3.2: Capacity Expansion of the Global T-Cell Lymphoma Market
- 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global T-Cell Lymphoma Market
- 6.3.4: Certification and Licensing
7. Company Profiles of Leading Players
- 7.1: Johnson & Johnson
- 7.2: Novartis
- 7.3: Bristol Myers Squibb Company
- 7.4: Merck
- 7.5: F. Hoffmann-La Roche
